Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Mol Cancer Ther. 2013 May 1;12(5):10.1158/1535-7163.MCT-12-1240. doi: 10.1158/1535-7163.MCT-12-1240

Figure 5. Expression of angiogenic factors by PC3/2G7 and PC3 tumors.

Figure 5

A. Representative images showing VEGFA (40×), CCL2 (40×) and VEGFR2 (10×) immunostaining of PC3/2G7 and PC3 tumors. The anti-VEGFR2 antibody recognizes both human and mouse VEGFR2, the anti-CCL2 is a human-specific antibody, and the anti-VEGFA antibody recognizes both human and mouse VEGFA. Images of CCL2 and VEGFA were obtained from paraffin-embedded sections; VEGFR2 images were from cryosections. B and C, qPCR analysis was carried out for the indicated mouse (m) and human genes (h) using species-specific primers and RNA isolated from n=10 PC3/2G7 tumors and n=12 PC3 tumors. ‘Total’ indicates qPCR primers did not distinguish mouse from human RNAs. B. VEGFA, VEGFR2 and CCL2 RNA levels. VEGFR2 RNA was significantly down regulated in PC3/2G7 tumors compared to PC3 tumors (p<0.0001, ***, two-tailed student’s test); CCL2 was significantly increased in PC3/2G7 compared to PC3 tumors (p<0.0001, ***, two-tailed student’s test). C. VEGFR2 RNA assayed using primers specific for human VEGFR2 and mouse VEGFR2, respectively, and also primers recognizing both mouse and human VEGFR2 (total VEGFR2). PC3 tumor cells expressed dramatically higher level of human (i.e., tumor cell-associated) VEGFR2 compared to PC3/2G7 tumor cells.